Bluejay Diagnostics releases IL-6 sepsis mortality risk data from SYMON-II study

Bluejay Diagnostics released baseline data from its SYMON-II clinical validation study evaluating IL-6 for 28-day mortality risk in sepsis. Non-survivors showed greater illness severity at baseline. The Symphony IL-6 test remains in development and is not cleared for commercial clinical use in the US.